Skip to content

AM Report: Severe Hypercalcemia Due to Elevated PTHrP

RANK-L

Thanks to Dr. Jarred Reed for an excellent presentation on workup and management of hypercalcemia

Learning Points:

  • Clinical manifestations of hypercalcemia include GI (anorexia, N/V), Neuro (weakness, AMS), Renal (polyuria, nephrocalcinosis), and MSK (fractures, osteopenia) symptoms. Causes may be broken down to PTH-mediated and PTH-independent causes.
  • Excess PTHrP (also called humoral hypercalcemia of malignancy) is the most common cause of hypercalcemia with non-metastatic solid tumors, and will result in a low or inappropriately normal PTH level.
  • The mainstay of management includes aggressive IVF but may require bisphosphonates, calcitonin, and corticosteroids. Use of Lasix is controversial but should largely be utilized to avoid fluid overload.
  • Denosumab may be used for refractory cases of hypercalcemia. Denosumab works on the OPG-RANK-RANKL pathway and prevents bone resorption by limiting RANKL driven osteoclast activity.

 

Back To Top
Login
Log in below to access learning modules.
Forgot Password
Enter your email address or username and we’ll send you instructions to reset your password.